IMMUNOME INC (IMNM)
US45257U1088 - Common Stock
ChartMill assigns a Buy % Consensus number of 87% to IMNM. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 33.92. This target is 105.42% above the current price.
IMNM was analyzed by 12 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about IMNM.
In the previous month the buy percentage consensus was at a similar level.
IMNM was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-31 | Piper Sandler | Initiate | Overweight |
| 2024-04-30 | JP Morgan | Initiate | Overweight |
| 2024-04-15 | Guggenheim | Initiate | Buy |
| 2024-04-01 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-01-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-12-19 | Wedbush | Initiate | Outperform |
| 2023-03-20 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-03-17 | Chardan Capital | Maintains | Buy |
| 2021-10-29 | Cantor Fitzgerald | Initiate | Overweight |